[{"orgOrder":0,"company":"Neopharm Labs Inc","sponsor":"UroGen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"DNA synthesis","graph1":"Oncology","graph2":"Approved","graph3":"Neopharm Labs Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"Neopharm Labs Inc \/ Neopharm","highestDevelopmentStatusID":"12","companyTruncated":"Neopharm Labs Inc \/ Neopharm"}]

Find Clinical Drug Pipeline Developments & Deals by Neopharm Labs Inc

Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Neopharm will lead the regulatory process in Israel, which is supported by the results from the Phase 3 OLYMPUS trial that showed Jelmyto achieved clinically significant disease eradication in adults with LG-UTUC.

                          Brand Name : Jelmyto

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 28, 2021

                          Lead Product(s) : Mitomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : UroGen Pharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank